Qiagen N.V. Common Shares (QGEN): Price and Financial Metrics
Qiagen N.V. Common Shares (QGEN)
Today's Latest Price: $40.45 USD
Updated Mar 27 12:00am
Add QGEN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
QGEN Stock Summary
- QGEN has a market capitalization of $8,988,788,740 -- more than approximately 87.32% of US stocks.
- With a one year PEG ratio of 214.16, Qiagen Nv is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 86.83% of US stocks.
- Price to trailing twelve month operating cash flow for QGEN is currently 27.17, higher than 90.57% of US stocks with positive operating cash flow.
- Stocks with similar financial metrics, market capitalization, and price volatility to Qiagen Nv are LOGM, CSII, SAIL, GRUB, and ATRS.
- Visit QGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.qiagen.com.
QGEN Stock Price Chart More Charts
QGEN Price/Volume Stats
| Current price | $40.45 | 52-week high | $43.16 |
| Prev. close | $40.81 | 52-week low | $25.04 |
| Day low | $39.90 | Volume | 2,164,000 |
| Day high | $40.68 | Avg. volume | 2,899,387 |
| 50-day MA | $37.20 | Dividend yield | N/A |
| 200-day MA | $36.25 | Market Cap | 9.21B |
Qiagen N.V. Common Shares (QGEN) Company Bio
Qiagen NV provides sample to insight solutions that transform biological samples into valuable molecular insights worldwide. The company was founded in 1986 and is based in Venlo, the Netherlands.
QGEN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $40.45 | $7.16 | -82% |
Below please find a table outlining a discounted cash flow forecast for QGEN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Qiagen Nv ranked in the 13th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for QGEN, they are:
- Qiagen Nv's effective tax rate, as measured by taxes paid relative to net income, is at 91 -- greater than 97% of US stocks with positive free cash flow.
- Qiagen Nv's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.05. This coverage rate is greater than that of only 17.97% of stocks we're observing for the purpose of forecasting via discounted cash flows.
- The weighted average cost of capital for the company is 10. This value is greater than 81.19% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -83% |
| 1% | -83% |
| 2% | -82% |
| 3% | -82% |
| 4% | -82% |
| 5% | -82% |
Want more companies with a valuation profile/forecast similar to that of Qiagen Nv? See A, VAR, ENDP, IDXX, and MGLN.
Loading social stream, please wait...